Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21942Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chatzikyriakidou, A. | en |
| dc.contributor.author | Voulgari, P. V. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T19:19:13Z | - |
| dc.date.available | 2015-11-24T19:19:13Z | - |
| dc.identifier.issn | 1873-0183 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21942 | - |
| dc.rights | Default Licence | - |
| dc.subject | Genetic Predisposition to Disease | en |
| dc.subject | HLA-B27 Antigen/*genetics/*metabolism | en |
| dc.subject | Humans | en |
| dc.subject | Models, Immunological | en |
| dc.subject | Polymorphism, Genetic | en |
| dc.subject | Protein Folding | en |
| dc.subject | *Spondylarthropathies/diagnosis/epidemiology/etiology/genetics | en |
| dc.subject | beta 2-Microglobulin/genetics | en |
| dc.title | What is the role of HLA-B27 in spondyloarthropathies? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.autrev.2011.01.011 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21296192 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S1568997211000267/1-s2.0-S1568997211000267-main.pdf?_tid=fa95a5347b43cf261049b9b7500a4268&acdnat=1333523587_ae48c9dec3e1dda15067a38926214aa7 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2011 | - |
| heal.abstract | HLA-B27 (Human Leukocyte Antigen-B27) accounts approximately for the one third of the overall genetic susceptibility to spondylorthropathies (SpAs). Up to 70 HLA-B27 subtypes have been reported all over the world with a decreasing north-south gradient of its frequency, which is reverse to that of endemic malaria. In an attempt to explain the possible role of HLA-B27 in SpAs pathogenesis, several theories have been suggested [1. Arthritogenic peptide, 2. Misfolding, 3. Cell surface HLA-B27 homodimers, 4. beta2m (beta2-microglobulin) deposition, 5. beta2m-free/peptide free heavy chains of HLA-I, 6. Enhanced survival of some microbes in HLA-B27 cells, 7. ERAP1/ERAP2 (endoplasmic reticulum aminopeptidases 1 and 2) and Tapasin function, 8. beta2m over-expression] each of which contributes up to a point to our understanding of HLA-B27 subtypes' role in SpAs manifestation. However, reviewing all the suggested hypotheses it seems logical to pass from a puzzle of distinct hypotheses to a global theory. This review summarizes the current knowledge of HLA-B27 aiming to understand its potential use in clinical practice of SpAs diagnosis and to direct its future studies. | en |
| heal.journalName | Autoimmun Rev | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Chatzikyriakidou-2011-What is the role of.pdf | 216.68 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
